Mosanna Therapeutics has secured $80m in a Series A funding round to advance a new nighttime nasal spray for obstructive sleep apnoea (OSA).
The company is developing MOS118, an easy-to-use nasal spray for OSA that helps restore the body’s natural airway control.
Go deeper with GlobalData
Pivotal bioVenture Partners and EQT Life Sciences headed the financing. Co-lead investors were Forbion, Broadview Ventures and Norwest.
Returning investors for this round were Supermoon Capital and High-Tech Gründerfonds (HTGF), and founding investor Forty51 Ventures.
EQT Life Sciences managing director Daniela Begolo stated: “What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue.
“MOS118 is the first therapy with the potential to restore the body’s natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOSA affects around one billion individuals worldwide and is associated with significant health risks such as hypertension and cardiovascular disease.
Current treatments often involve mechanical solutions that can be uncomfortable for patients.
Mosanna’s MOS118 nasal spray aims to address these issues by targeting upper airway muscles to maintain airway patency during sleep.
The new funding will support the spray through its Phase II development while also expanding Mosanna’s product pipeline.
Mosanna has appointed Dr David Weber as president and CEO to guide the next stage of the company’s growth.
Pivotal bioVenture partner Jeni Lee stated: “With his deep expertise in biotech innovation and patient-centric therapies, Dr Weber was the ideal choice to lead Mosanna into the next chapter.
“We look forward to partnering with him and the Mosanna team to deliver on the promise of this life-changing sleep apnoea treatment.”
